This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Korea Institute of Science and Technology, University of Ulsan Foundation for Industry Cooperation. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 2,253 
1 out of 95 
Years Active: 2022
Title: Seong-Su Kim: Innovator in Ischemia-Reperfusion Injury Treatment
Introduction
Seong-Su Kim is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of ischemia-reperfusion injury. His innovative work has led to the development of a unique composition that holds promise for medical applications.
Latest Patents
Seong-Su Kim holds 1 patent for his invention titled "Composition comprising extract for preventing or treating ischemia-reperfusion injury and use thereof." This patent provides a pharmaceutical composition that includes an extract as an active ingredient. The method described in the patent aims to prevent or treat ischemia-reperfusion injury in subjects using either a food composition or the pharmaceutical composition.
Career Highlights
Throughout his career, Seong-Su Kim has worked with esteemed institutions such as the Korea Institute of Science and Technology and the University of Ulsan Foundation for Industry Cooperation. His experience in these organizations has allowed him to advance his research and contribute to the scientific community.
Collaborations
Seong-Su Kim has collaborated with notable colleagues, including Chu Won Nho and Hak Cheol Kwon. These partnerships have facilitated the exchange of ideas and fostered innovation in their respective fields.
Conclusion
Seong-Su Kim's contributions to the treatment of ischemia-reperfusion injury through his patented composition highlight his role as an influential inventor. His work continues to inspire advancements in pharmaceutical research and development.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile